Skip to main content
Pacgen Life Science Corporation logo

Pacgen Life Science Corporation — Investor Relations & Filings

Ticker · PBS ISIN · CA69374M1041 TSXV Human health and social work activities
Open in API
Filings indexed 147 across all filing types
Latest filing 2020-11-30 Regulatory Filings
Country CA Canada
Listing TSXV PBS

About Pacgen Life Science Corporation

www.pacgenlife.com

Pacgen Life Science Corporation is a life sciences company operating a dual business model centered on commercial distribution and advanced diagnostic services. The company maintains a commercial platform for marketing and distributing consumer health products, including oral care, skin care, and health supplements. Concurrently, through its DAP ISO 15189 Accredited facility, Danner Laboratory, Pacgen provides high-precision clinical laboratory testing and outsourcing solutions. These services specialize in molecular diagnostics, utilizing technologies like real-time PCR and rapid multi-flex molecular testing for infectious disease indication, including HPV, viral, and bacterial pathogens. The company serves clinics, medical entities, and individuals requiring accurate and timely diagnostic information for patient care and self-maintenance.

Recent filings

Filing Released Lang Actions
Notice.pdf
Regulatory Filings
2020-11-30 English
News release - English.pdf
Delisting Announcement Classification · 95% confidence The document is a press release announcing the completion of a statutory plan of arrangement under the Business Corporations Act, where General Biologicals Corporation acquired all issued shares of Pacgen Life Science Corporation. It mentions the anticipated delisting of Pacgen Shares from the TSX Venture Exchange. The document includes details about shareholder approval percentages, the process for shareholders to receive cash consideration, and references to regulatory approvals. There are no financial statements or detailed financial data presented, nor is this a full report or filing. The document is an official announcement of a delisting event and completion of a corporate restructuring transaction. Therefore, it fits the category of a Delisting Announcement (DLST). The document length is 3548 characters, which is consistent with an announcement rather than a full report. Confidence is high given the clear mention of delisting and arrangement completion.
2020-09-30 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release announcing the voting results of a shareholder meeting where an acquisition by General Biologicals Corporation was approved. It includes details about the special resolution, election of directors, appointment of auditors, and stock option plan approval. The document also mentions the expected completion date of the acquisition and provides forward-looking statements. There are no detailed financial statements, comprehensive financial performance data, or full report content. The document is primarily an announcement of voting results from a shareholder meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3057 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is DVA with high confidence.
2020-09-16 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2020-08-31 English
Interim MD&A - English.pdf
Regulatory Filings
2020-08-31 English
Interim financial statements/report – English.pdf
Regulatory Filings
2020-08-31 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.